Michael N. Murdock
Known title: See RemarksCIK: 0001316102
Associated companies
Transaction History
| RDNT | ▲ Buy | Grant | 6,613 | $0 | 3/3/2026 | View on chart |
| RDNT | ▼ Sell | Gift | 3,000 | $0 | 11/13/2025 | View on chart |
| RDNT | ▼ Sell | Open Market | 11,132 | $646K | 6/5/2025 | View on chart |
| RDNT | ▲ Buy | Grant | 11,072 | $0 | 1/8/2025 | View on chart |
| RDNT | ▼ Sell | Gift | 5,000 | $0 | 12/2/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 9,329 | $588K | 8/21/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 4,191 | $259K | 8/21/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 1,480 | $94K | 8/21/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,000 | $625K | 6/12/2024 | View on chart |
| RDNT | ▼ Sell | Gift | 5,000 | $0 | 6/7/2024 | View on chart |
| RDNT | ▲ Buy | Grant | 9,711 | $0 | 1/9/2024 | View on chart |
| RDNT | ▼ Sell | Open Market | 10,115 | $354K | 12/5/2023 | View on chart |
| RDNT | ▼ Sell | Gift | 5,000 | $0 | 11/20/2023 | View on chart |
| RDNT | ▲ Buy | Grant | 15,790 | $0 | 1/3/2023 | View on chart |
| RDNT | ▲ Buy | Grant | 10,000 | $0 | 1/4/2022 | View on chart |
| RDNT | ▼ Sell | Gift | 10,000 | $0 | 12/7/2021 | View on chart |
| RDNT | ▲ Buy | Grant | 1,837 | $0 | 9/21/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
RadNet Q2 Earnings and AI Study News
RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.
RadNet Q2 Earnings and AI Study News. RadNet received positive marks for its second-quarter testing and diagnostics services earnings. Additionally, a new study suggests DeepHealth AI could help avoid nearly one in five prostate biopsies. These developments provide context for the stock's current position within its 52-week range.